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OBJECTIVES To assess the potential of the donor heart to respond to interleukin-6 (IL6), the present study
investigated the expression of IL6 receptor components in the myocardium of donor hearts
before transplantation.
BACKGROUND Donor heart dysfunction early after transplantation has been associated with the cytokine
storm after donor brain death. Proinflammatory cytokines are thought to play a central role
in this process. Interleukin-6 is of specific interest because it has been associated with cardiac
allograft dysfunction and is related to an impaired prognosis. Its action requires expression of
the specific IL6 receptor (IL6R), and the common signal transducer of the IL6 family
glycoprotein 130 (gp130) in the donor heart.
METHODS The activation of IL6, IL6R and gp130 messenger ribonucleic acid (mRNA) and protein was
studied via reverse transcription-polymerase chain reaction (RT-PCR) and immunohistology
in donor hearts (n  6) and compared with patients undergoing evaluation of ventricular
arrhythmias (control, n  9) or with advanced heart failure (n  20).
RESULTS Messenger RNA of IL6, IL6R and gp130 was strongly expressed in all chambers of donor
hearts, whereas right ventricles of control patients did not show any expression (donor vs.
control: p  0.005). Right ventricles of failing hearts showed IL6, IL6R and gp130 mRNA
levels comparable with those found in donor hearts. Immunohistochemistry paralleled the
RT-PCR data on the protein level. While IL6 was mainly expressed by myocytes, both
receptor components were preferentially found mainly on interstitial cells.
CONCLUSIONS The expression of the IL6 receptor components in the donor heart before transplantation
establishes the condition sine qua non for the response of the donor heart to circulating IL6.
This mechanism may explain the close association of elevated IL6 serum levels to acute
cardiac allograft dysfunction in the early perioperative period. (J Am Coll Cardiol 2002;39:
1508–12) © 2002 by the American College of Cardiology Foundation
Primary cardiac allograft failure, that is, myocardial failure
unexplained by hyperacute rejection, acute rejection or
surgical problems, accounts for roughly 25% of early deaths
after cardiac transplantation (1). One potential mechanism
to explain nonspecific graft failure is donor heart dysfunc-
tion after the neurohormonal and cytokine storm associated
with brain death. Expression of proinflammatory cytokines
in the hearts of brain-dead rats has been demonstrated (2,3).
Cardiac dysfunction is mediated by several proinflamma-
tory cytokines. Besides interleukin-1 (4–7) and tumor
necrosis factor (8–11), interleukin-6 (IL6) has been inten-
sively investigated. Interleukin-6 levels are elevated in the
circulation of patients with asymptomatic left ventricular
dysfunction and symptomatic congestive heart failure (12–
14). In patients with advanced heart failure undergoing
transplantation, IL6 serum levels are correlated with a
reduction in myocardial contractility (15). Interleukin-6 and
its specific receptor (IL6R) are upregulated in the failing
myocardium, and both are modulated in the process of
cardiac remodeling after left ventricular assist device im-
plantation (16–18).
After transplantation, IL6 is of specific interest because it
has been associated with cardiac allograft dysfunction early
after cardiac transplantation in the absence of cellular
rejection and related to an impaired prognosis (15,19).
Interleukin-6 serum levels are increased not only in the
recipient of the graft but also in the brain-dead donor
(20,21). Furthermore, IL6 messenger ribonucleic acid
(mRNA) is expressed in donor hearts before alloantigen
contact (21). Substitution of hormones antagonistically
influencing IL6 effects including corticosteroids (22), tri-
iodothyronine (23) and arginine vasopressin (24), has been
shown to be of benefit in the maintenance of donor heart
function after brain death before explantation. Taken to-
gether, these data indicate that IL6 may impact negatively
on donor heart function.
Interleukin-6 is a member of a structurally related cytokine
family—including IL6, interleukin-11, cardiotrophin-1,
oncostatin-M, leucemia-inhibitory factor and ciliary neurotro-
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phic factor—with overlapping biologic effects (25). The redun-
dancy and functional pleiotropy of the IL6 cytokine family in
a wide variety of tissues and cells can be explained on the
molecular level by the use of shared receptor subunits (26).
Interleukin-6 signals through a receptor complex that is com-
posed of the IL6R and the common signal transducer glyco-
protein 130 (gp130).
Although several authors hypothesize an impact of ele-
vated circulating IL6 levels on donor heart dysfunction as
mentioned in the preceding text, little is known about the
potential responsiveness of the donor heart towards an
“IL6-activated” recipient in the perioperative period after
transplantation. This potential depends on the expression of
both IL6 receptor components, IL6R and gp130, in the
donor heart. Until now, data on the expression of these
components in the donor heart before explantation are not
available. Therefore, the present study evaluates the expres-
sion of IL6R and gp130 together with IL6 in the donor
heart.
METHODS
Human myocardial tissue. Nonfailing human myocar-
dium (normal ejection fraction by echocardiographic exam-
ination; absence of cardiovascular medication in patient
history; inotropic support only with dopamine, but not
high-dose isoprenaline or noradrenaline) was obtained from
six donors who suffered from brain death as a result of
traumatic injury but could not be transplanted for nonmed-
ical reasons. Before acceptance and explantation of the
donor heart, functional data demonstrating adequate quality
were given to the attending cardiologist and the cardiac
surgeon in the transplant center. Subsequent to explanta-
tion, these nonfailing hearts could not be used for trans-
plantation because of technical or logistic reasons (27). Nine
heart specimens of patients with normal ventricular function
undergoing right ventricular (RV) biopsy for evaluation of
ventricular arrhythmias (four Brugada syndrome, five ar-
rhythmogenic RV disease) served as controls. In addition,
RV myocardium of failing hearts (patients undergoing heart
transplantation, n 20) was investigated (18). The protocol
was approved by the ethics committee of Muenster Univer-
sity Hospital, Muenster, Germany.
Tissue preparation. Myocardial samples were retrieved in
the operating room immediately after native hearts had been
excised (donor heart samples, right ventricle of patients
suffering from advanced heart failure) or in the biopsy suite
after removal with the bioptome (control samples). Imme-
diately after removal, specimens representing the left and
right ventricle were snap frozen in liquid nitrogen. Care was
taken in ischemic cardiomyopathy patients to avoid sam-
pling of scarred areas. Until use, the tissue was stored at
80°C.
Cytokine detection. Interleukin-6, IL6R, gp130 and
glyceraldehyde-3-phosphate-dehydrogenase (G3PDH)
mRNA in heart samples were assessed by reverse transcription-
polymerase chain reaction (RT-PCR). Total ribonucleic acid
of myocardial samples (donor and failing hearts) was isolated,
as previously described (28). To isolate mRNA from biopsies,
the MACS system (Miltenyi Biotec, Nordrhein-Westfalen,
Bergisch Gladbach, Germany) was used. Each ribonucleic acid
sample was reverse transcribed using Superscript II according
to the manufacturer’s instructions (Life Technologies, Eggen-
stein, Germany). The polymerase chain reaction (PCR) was
done in a total volume of 100 l using 1  buffer (20 mM
Tris-HCl [pH 8.4], 50 mM KCl), 1.5 mM MgCl2, 0.1 mM
of each dNTP, 2.5 U Taq Polymerase (Life Technologies) and
0.5 M of each primer (IL6: left primer: CACAGACAGC-
CACTCACCTCTTC, right primer: CTGCGCAGAAT-
GAGATGAGTTGTC; IL6R: hINF3G-IL6R, MBI, St.
Leon-Rot, Germany; gp130: left primer: CCACCCGATCT-
TCATTCACT, right primer: TAGTCCATTCCACCCA-
AAGC; G3PDH: left primer: GTCAGTGGTGGACCT-
GATCT, right primer: TGAGCTTGACAAAGTGGTCG).
Product sizes were 464 base pair (bp) (IL6), 300 bp (IL6R),
498 bp (gp130) and 212 bp (G3PDH). Amplification was
carried out in an UNO thermocycler (Biometra, Go¨ttingen,
Germany) after an initial denaturation at 95°C for 5 min.
The following cycle profile was used: denaturation at 95°C
for 60 s, primer annealing at 55°C for 70 s, primer extension
at 72°C for 60 s and a final extension of 72°C for 10 min.
Aliquots of the PCR products were analyzed using standard
agarose gel electrophoresis, a video documentation system
and ImageQuant software (Molecular Dynamics, Krefeld,
Germany).
Immunohistochemistry. The IL6 system was detected as
follows: 1) for IL6, rabbit anti-human IL6 (H-183, sc-
7920; Santa Cruz, Heidelberg, Germany); 2) for IL6R,
rabbit anti-human IL6R (C-20, sc-661; Santa Cruz); and 3)
for gp130, rabbit anti-human gp130 (C-20, sc-655, Santa
Cruz) were used. The secondary antibody/detection system
was donkey anti-rabbit immunoglobulin conjugated to
Texas Red (Chemicon International, Hofheim, Germany).
The immunohistochemical staining procedure was per-
formed with modifications, as described (29). In brief,
cryosections were incubated with the respective antibody
(1:200) at room temperature for 1 h. After washing thor-
oughly in PBS, sections were treated with the secondary
antibody (1:500) for 1 h at room temperature. After
Abbreviations and Acronyms
bp  base pair
gp130  glycoprotein 130
G3PDH  glyceraldehyde-3-phosphate-dehydrogenase
IL6  interleukin-6
IL6R  interleukin-6-receptor
mRNA  messenger ribonucleic acid
PCR  polymerase chain reaction
RT-PCR  reverse transcription-polymerase chain
reaction
RV  right ventricular
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washing again, the slides were mounted with fluoromount
mounting medium (BDH, Poole, United Kingdom). Neg-
ative controls included substitution of the primary antibody
by rabbit immunoglobulins or omission of the primary
antibody. Results were documented using a fluorescence
microscope (AXIOPHOT2, Zeiss, Jena, Germany) fitted
with the appropriate filter blocks for detection of Texas Red
fluorescence.
Statistics. For statistical analysis, the Statistical Package
for the Social Sciences (SPSS 9.0, SPSS Inc., Chicago,
Illinois) was used. Comparisons between optical density
ratios of cytokine (receptor)/G3PDH mRNA of donor and
control tissues were carried out by Mann-Whitney U test
for independent samples. P values of0.05 were considered
significant.
RESULTS
mRNA expression of IL6, IL6R and gp130. Myocardial
samples of all chambers of donor hearts, RV biopsy speci-
mens of patients undergoing evaluation of ventricular ar-
rhythmias (control) and the right ventricle of patients
undergoing heart transplantation were analyzed for the
expression of IL6, IL6R and gp130 mRNA by RT-PCR
(Table 1). The RV control biopsies did not show detectable
expression of IL6, IL6R and gp130 mRNA. In contrast
with the controls, donor hearts and failing hearts strongly
expressed the mRNAs of IL6, IL6R and gp130 (p 0.005).
In donor hearts, the components of the IL6 system were
strongly expressed in all right and left ventricles and atria.
Differences between the chambers were not observed. The
right ventricles of patients suffering from advanced heart
failure showed high IL6, IL6R and gp130 mRNA levels. In
comparison with the expression levels found in failing
hearts, the RV mRNA levels of IL6, IL6R and gp130 in
donor hearts were not significantly lower.
Immunohistochemical demonstration of the IL6, IL6R
and gp130 distribution patterns. In order to demonstrate
that the elevated mRNA levels of IL6, IL6R and gp130 in
donor hearts were translated into protein, sections from the
right and left ventricular myocardium of donor hearts and
the RV biopsies controls were immunostained with rabbit
anti-IL6, IL6R and gp130 antibodies (Fig. 1). The myo-
cardium of the control biopsies were devoid of immuno-
labeling for IL6, IL6R and gp130. In the ventricles of donor
hearts, IL6 and both of its receptor components were found.
The immunostaining of all components of the IL6 system
was distributed in patchy fashion over the entire myocar-
dium and bound to cellular structures. Interleukin-6 was
mainly produced by a subpopulation of cardiomyocytes but
was also strongly expressed by some interstitial cells, prob-
ably fibroblasts. In comparison, strong labeling for IL6R
and gp130 was located mainly on interstitial cells; only few
myocytes stained weakly. In failing hearts, the distribution
patterns were similar to those found in donor hearts.
Table 1. Expression Levels of IL6, IL6R and gp130 in CTRL Biopsies, All Chambers of Donor Hearts and RV of FH
mRNA Ratio
CTRL
(n  9)
FH
(n  20) Donor Hearts (n  6)
RV RV RV LV RA LA
IL6/G3PDH 0 2.2  1.2† 1.3  0.9† 1.4  0.3† 1.5  1.1† 1.6  0.3†
IL6R/G3PDH 0 1.9  1.0† 1.3  0.5† 0.9  0.6† 1.4  0.8† 1.0  0.6†
gp130/G3PDH 0 2.0  1.2† 1.3  0.4† 1.6  0.7† 0.5  0.1† 1.1  1.0*
Versus control *p  0.05; †p  0.005.
CTRL  control hearts, myocardium of patients undergoing evaluation of ventricular arrhythmias; FH  failing hearts, myocardium of patients undergoing heart
transplantation; G3PDH  glyceraldehyde-3-phosphate-dehydrogenase; gp130  glycoprotein 130; IL6  interleukin-6; IL6R  interleukin-6-receptor; LA  left atrium;
LV  left ventricle; mRNA  messenger ribonucleic acid; RA  right atrium; RV  right ventricle.
Figure 1. Immunohistochemistry demonstrating the distribution patterns
of interleukin-6 (IL6), interleukin-6-receptor (IL6R) and glycoprotein 130
(gp130) in donor hearts and controls. Fluorescence visualization of gp130,
IL6R and IL6 using rabbit anti-human antibodies and, as secondary
antibody/detection system, donkey anti-rabbit conjugated with Texas Red.
Control hearts, myocardium of patients undergoing evaluation of ventric-
ular arrhythmias (CTRL) gp130, IL6R and IL6 were not found in control
biopsies. Ventricles of donor hearts (DONOR HEART) gp130, IL6R and
IL6 occurred in all right ventricular specimens of donor hearts (arrows).
Glycoprotein 130 and IL6R were located in interstitial cells, preferentially
fibroblasts and myocytes. Interleukin-6 label was mainly detected on
myocytes, but also some interstitial fibroblasts were strongly stained.
Autofluorescence of the lipofuscin bodies (lf) was evaluated by using the
FITC filter (arrowheads  identical distribution patterns). Original
magnification: 200.
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However, the expression by interstitial cells was more
pronounced for all components of the IL6 system (data not
shown).
DISCUSSION
Our data demonstrate for the first time that, concomitantly
with IL6, both components of the IL6 receptor, that is, the
specific subunit IL6R and the common signal transducer
gp130: 1) are induced in all cardiac chambers of brain-dead
donors before removal for transplantation; 2) are expressed
at levels comparable to failing hearts in hearts of brain-dead
donors; and 3) show similar distribution patterns on the
cellular level in donor hearts and failing hearts.
Brain death activates the cardiac IL6 system. The lack of
expression of IL6 receptor components in control biopsies
obtained from arrhythmia patients with hemodynamic and
echocardiographic evidence of normal heart function sug-
gests that the expression of the IL6 receptor components as
well as IL6 in donor hearts may be induced by the sequelae
of brain death. Brain death itself causes a massive disruption
in the hemodynamic, hormonal and cytokine homeostasis
(30). In the rat model, donor brain death stimulates expres-
sion of inflammatory cytokines, including IL6 in the heart
and other peripheral organs (2). Furthermore, a differential
expression has been suggested between organs from living
donors compared with organs from cadaveric donors regard-
ing the cytokines tumor necrosis factor-alpha, IL6 and
interleukin-8 (31). In the human system, analogies can be
drawn from the field of renal transplantation. Renal allo-
grafts obtained from cadaveric donors show elevated cyto-
kine levels compared with living donations (32). This is
reflected in our study by the massive activation of IL6 and
its receptor components in donor hearts compared with
endomyocardial biopsies obtained from control patients.
With this demonstration of an upregulation of the IL6
receptor system in the donor heart after brain death, it is
likely that circulating IL6, either generated by the donor
heart itself as shown here or by the recipient due to
advanced heart failure or after cardiac surgery, exerts its
negative inotropic effects on the donor myocardium (33),
thereby producing the clinical syndrome of early perioper-
ative donor heart dysfunction (34). Thus, the responsiveness
of the donor heart to circulating IL6 in the immediate
perioperative period based on the pre-existent expression of
IL6 receptor components may explain the phenomenon of
early “unexplained” graft failure.
Activation of donor hearts is comparable to failing
hearts. Our study extends recent data (35) demonstrating
similar left ventricular IL6 mRNA expression levels in
donor and failing hearts. While our data show comparable
levels of gp130 in all chambers of donor hearts, the study of
Eiken et al. (35) revealed a stronger expression of gp130 in
left atria than in left ventricles. This discrepancy may be due
to differences in the recruitment of the samples. Investigat-
ing donor heart malfunction, Birks et al. (11,21) demon-
strated that transplanted donor hearts—comparable to our
donor cohort—and failing hearts expressed similar levels of
tumor necrosis factor-alpha and IL6 mRNA. In their study,
circulating levels of IL6 were increased eight- to ninefold in
comparison with normal subjects. Taken together, these
data indicate that the donor heart is able to respond to
circulating IL6 in the immediate perioperative period and,
therefore, support a role of the IL6 system in the syndrome
of early unexplained allograft failure.
The IL6 system is activated in cardiomyocytes and
fibroblasts. In our study, upregulaton of mRNA was par-
alleled by corresponding protein distribution patterns of all
components of the IL6 system. Immunohistochemistry
revealed that the patterns are comparable in donor hearts
and failing hearts, while controls did not show immunola-
beling. The predominant expressing cell population was
located in the interstitium, preferentially fibroblasts. It has
been shown previously in cell culture studies that IL6 and
other members of this cytokine family are expressed by
interstitial fibroblasts (36,37). However, to our knowledge
no data are available on the expression of the IL6 receptor
components in cardiac interstial fibroblasts. As additional
expressing cell types, myocytes and microvascular endothe-
lial cells were identified. Expression of IL6 in the vascula-
ture has been reported before (38). Studies on the role of
interleukin-1-beta—another proinflammatory cytokine—in
congestive heart failure showed similar cellular distribution
patterns as those described in the present study for IL6, that
is, expression by cardiac monocytes and fibroblast, vascular
cell types and infiltrating cells (7). On the other hand,
Eicken et al. (35) demonstrated only cardiomyocytes as
major producers of IL6 and gp130 in failing hearts and
suggest a similar expression pattern in donor hearts. This
discrepancy in the cell populations producing IL6 and
gp130 may be due to the different methodologic approaches
used, that is, differences in fixation or in the embedding
procedure. Nevertheless, our data demonstrate that both
IL6 and its receptor components are induced not only in
myocytes but also in fibroblasts. Therefore, we postulate
that in donor hearts as well as failing hearts both cell types
harbor the potential to respond to circulating and locally
produced IL6 and, through these complementary pathways,
may mediate not only acute cardiac allograft dysfunction but
also set the stage for chronic transplant vasculopathy.
Conclusions. Expression of IL6 and its receptor compo-
nents is intensely stimulated in the myocardium of brain
dead donors comparable to patients with advanced heart
failure in comparison with a control group not compromised
by the sequelae of brain death. The induction of the IL6
receptor system in the donor heart before transplantation
establishes the condition sine qua non for the response of
these hearts to circulating and locally produced IL6 in the
immediate perioperative period, which may explain the
close association of IL6 serum levels to acute cardiac
allograft dysfunction. This might have important therapeu-
tic implications.
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